Dopaminergic News and Research

RSS

Autonomous glial mechanism may drive circadian rhythms

Glial cells of the nervous system, once thought to function strictly as support cells for neurons, are now thought to actively modulate them.

2 Aug 2007

UAB receives grants to investigate novel approaches to treat Parkinson's disease

The Michael J. Fox Foundation (MJFF) has awarded two research grants to UAB (University of Alabama at Birmingham) researchers to investigate novel approaches to treat Parkinson's disease.

13 Jul 2007

Cigarette smoking associated with reduced risk for developing Parkinson's disease

A pooled analysis of data from previous studies suggests that cigarette smoking appears to be associated with a reduced risk for developing Parkinson's disease, with long-term and current smokers at the lowest risk, according to a report in the July issue of Archives of Neurology.

10 Jul 2007

New insight into neural stem cells

Scientists have discovered that adult neural stem cells, which exist in the brain throughout life, are not a single, homogeneous group.

9 Jul 2007

People with narcolepsy have a high frequency of REM sleep without muscle atonia

Normal rapid eye movement (REM) sleep is characterized by tonic features, including cortical electroencephalogram (EEG) desynchronization and muscle atonia, as well as phasic events, including bursts of REM, phasic activities of both chin and limb electromyography (EMG), and cardiorespiratory variability.

4 Jul 2007

PINK1 protects from Parkinson's

Parkinson disease (PD) is a common neurodegenerative disease characterized by the selective loss of midbrain dopaminergic neurons.

19 Jun 2007

Implanting dopamine generators in brain cells improves Parkinson's in monkeys

Implanting dopamine generators (dopaminergics) in brain cells has produced improvement in the symptoms in Parkinson's, according to the results of tests carried out with monkeys by the Navarra University Hospital, led by Dr Mar'a Rosario Luquin Piudo, neurologist at the Hospital and at the other Navarra University-based medical centre, CIMA (the Research Centre for Applied Medicine).

17 May 2007

Coenzyme Q10 does not improve Parkinson's disease symptoms

Small doses of the antioxidant coenzyme Q10 appear to increase blood levels of this naturally occurring compound in patients with Parkinson's disease, but does not improve Parkinson's disease symptoms, according to an article posted online today that will appear in the July 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.

15 May 2007

Avicena files composition of matter patent application for treatment of Parkinson's disease

Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.

27 Apr 2007

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

All physicians involved in the treatment of PBS/IC understand that the placebo effect likely plays a major role in treatment, and is important when evaluating drug trials.

19 Apr 2007

Jefferson participates in global study to extend effectiveness of drug for Parkinson's

After Parkinson's disease patients use the drug levodopa or L-dopa for several years as a treatment for restoring the cellular communication that controls muscle movement by replacing lost dopamine, they begin to experience motor complications that include a shortened response to each dose of L-dopa.

19 Apr 2007

Research into Parkinson's Disease receives a boost

Research into Parkinson's Disease at the University of Dundee has received a boost from a fundraising campaign organised by the Falkirk Branch of the Parkinson's Disease Society.

29 Jun 2006

Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors

Understanding what makes people crave the high of nicotine is a key to developing treatment for this highly addictive drug.

14 Jun 2006

Midbrain, striatal and amygdalar dopaminergic dysfunction in ADHD

The brain's dopamine system, which has long been associated with reward learning and reward-related behavior, works differently in treated and untreated attention deficit hyperactivity disorder (ADHD) individuals.

7 Jun 2006

Prefrontal cortex in the brain damaged by both alcoholism and chronic smoking

Alcoholism is commonly associated with chronic smoking, and both alcohol and nicotine are believed to act on the same brain region. Research builds upon previous research that identified four potential alcohol-sensitive genes in the prefrontal cortex, finding that smoking also influences the expression of these genes.

26 Apr 2006

SRY gene directly controls neuronal function in the brain

Shaped by much previous research, the prevailing view regarding sex-specific differences in the brain is that they are caused by circulating sex hormones, which are generated outside the brain and influence certain aspects of brain development, as well as brain function in adults.

23 Feb 2006

Animal model of Parkinson's disease reveals striking sensitivity to common environmental toxins

In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.

7 Sep 2005

Rotenone study may lead to novel therapies for Parkinson's disease

Neuroscientists from the University at Buffalo have described for the first time how rotenone, an environmental toxin linked specifically to Parkinson's disease, selectively destroys the neurons that produce dopamine, the neurotransmitter critical to body movement and muscle control.

23 Aug 2005

A protein found naturally in the brain may protect against Parkinson's disease

The findings also may lead to an improved understanding of a disorder called early-onset torsion dystonia.

2 Jun 2005

Findings could lead to improved treatments for schizophrenics, amphetamine abusers

An Oregon Health & Science University researcher is among an international team closing in on why many people with schizophrenia and other psychotic disorders are "supersensitive" to the powerful neurotransmitter dopamine.

10 Apr 2005